Constantly outperforming industry standards by developing biosimilars with next generation technology
Biological drugs are based on proteins as active substances. Proteins are so complicated in their molecule structure that they need to be produced through introduction of a DNA sequence in a living cell instructing it to produce the desired target protein. This is much more complicated and costly than the synthetic production process used for smaller molecules which constitute the active substances in traditional drugs. The high production cost leads to high prices and low accessibility of biological drugs particularly in developing countries. Xbranes patented protein production technology enables a significantly more cost efficient production process of biological drugs compared to standard systems in bacteria cells of the form E.coli. The technology makes it possible for Xbrane to introduce affordable generic versions (or biosimilars) of critical biological drugs in developing countries as well as to realize significant cost savings for burdened health care systems in the developed countries.
+8X MORE PRODUCTIVE AND UP TO 85% LOWER PRODUCTION COST VS. STANDARD SYSTEMS
The unique strength with our patented protein production technology is the high production yield we can achieve and the resulting low cost of protein production. We have with our technology and know-how in protein production helped our customers to increase their production yield with on average 8x across multiple different therapeutic proteins. Academic studies have demonstrated an up to 50x higher yield for our patented technology compared to industry standard systems in E. coli (BL21 (DE3))*. In production of our own bioslmilars we currently have reached 7x higher yield with our technology compared to industry standards in E. coli (Bl21 (DE3)), a competitive edge we believe will be crucial for long term commercial success in the biosimilar market as it results in a superior cost position compared to competition.
*In total 10 different customer projects for pharma and life science clients . **Optimisation of Over-Expression in E. coli and Biophysical Characterisation of Human Membrane Protein Synaptogyrin ***Indicative indexed production cost per dose
Xbrane has developed superior, versatile and easy to use systems for the production of proteins in E. coli. Xbrane’s systems allow tuning the intensity of expression of the genes encoding recombinant proteins in an unprecedented accurate manner.
The systems have successfully been used for maximizing the production of both routine and difficult to express proteins. Compared to standard protein production systems, improvements of production yields of up to 50-fold have been observed. Importantly, the systems allow operating in an exceptionally cost- and time-efficient manner.
Xbrane has over the years developed an extensive know how of protein production. This know how has been converted in to a tool box of different biological tools which could by combining them differently boost the production levels and lower the total cost of production.
Lucentis, Cimzia and Oncaspar are registered trademarks of their respective owners.
ARE YOU INTERESTED IN OUR APPROACH?
If you are seeking to increase your production levels or have difficulties producing your target, let us help you with our unique technology and know how.